Allogene Therapeutics (ALLO) Other Non Operating Income (2018 - 2026)

Allogene Therapeutics has disclosed Other Non Operating Income across 9 years of filings, most recently posting $212000.0 for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $212000.0, up 130.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $335000.0 (up 111.56% YoY), and the FY2025 annual result was $215000.0, up 105.48% from the prior year.
• Other Non Operating Income came in at $212000.0 for Q1 2026 at Allogene Therapeutics, down from $247000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $2.1 million in Q1 2023 to a low of -$6.9 million in Q4 2023.
• The 5-year median for Other Non Operating Income is -$929000.0 (2024), against an average of -$1.5 million.
• Across the five-year window, Other Non Operating Income sank 651.22% in 2022 and jumped 130.43% in 2026, its largest moves.
• Allogene Therapeutics' Other Non Operating Income stood at -$3.6 million in 2022, then plunged by 90.65% to -$6.9 million in 2023, then surged by 71.85% to -$2.0 million in 2024, then surged by 112.65% to $247000.0 in 2025, then fell by 14.17% to $212000.0 in 2026.
• The last three Other Non Operating Income figures came in at $212000.0 (Q1 2026), $247000.0 (Q4 2025), and -$81000.0 (Q3 2025), per Business Quant data.